MRC1 and neoplasm: For instance, blocking pro-angiogenic factor angiopoitin-2 leads to angiogenesis inhibition and tumor hypoxia, however subsequent enhancement in recruitment of MRC1+ TEMs limits the efficacy of ANG-2 blockade [48, 49].